Plasminogen Activator Type 1 (Hf Epitope) 抗体
适用: 人
Func, WB
宿主: 小鼠
Monoclonal
MA-33H1F7
unconjugated
(4 references)-
- 抗原
- Plasminogen Activator Type 1
- 抗原表位
- Hf Epitope
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- 非结合性
- 应用范围
- Functional Studies (Func), Western Blotting (WB)
- 交叉反应 （详细）
- Cross reactivity: Mouse, rat : Yes
- 过滤
- 0.2 μm filtered
- 克隆位点
- MA-33H1F7
- 亚型
- IgG1
-
-
- 应用备注
- For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be optimized in user's experimental setting.
- 限制
- 仅限研究用
-
- 缓冲液
- PBS, containing 0.1 % bovine serum albumin.
- 储存条件
- 4 °C
- 储存方法
- Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
-
-
: "Redirection of the reaction between activated protein C and a serpin to the substrate pathway." in: Thrombosis research, Vol. 122, Issue 3, pp. 397-404, (2008) (PubMed).
: "Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles." in: Thrombosis and haemostasis, Vol. 86, Issue 6, pp. 1528-31, (2002) (PubMed).
: "Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells." in: Hypertension, Vol. 37, Issue 3, pp. 961-6, (2001) (PubMed).
: "Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms." in: Biochimica et biophysica acta, Vol. 1337, Issue 2, pp. 257-66, (1997) (PubMed).
-
: "Redirection of the reaction between activated protein C and a serpin to the substrate pathway." in: Thrombosis research, Vol. 122, Issue 3, pp. 397-404, (2008) (PubMed).
-
- 抗原
- Plasminogen Activator Type 1
- 背景
- Plasminogen activator inhibitor type-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily, is an important protein in the regulation of fibrinolysis. PAI-1 is unique among the serpins because of its functional and conformational flexibility. PAI-1 is the most important physiological inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u- PA). Increased PAI-1 levels are associated with thrombotic events and is an established risk factor for cardiovascular diseases. The active conformation PAI-1 inhibits its target proteinases by the formation of a stable, inactive complex. Although PAI-1 is synthesized as an active molecule, it converts spontaneously to an inactive, latent form that can be partially reactivated by denaturing agents. In addition, a third conformation reacting as a non-inhibitory substrate towards various target proteinases has been identified. The epitope of monoclonal antibody MA-33H1F7 is predominantly composed of three residues 154 130 131 (Lys /Glu /Arg ), positioned virtually linearly in the three-dimensional structure. The epitope of the antibody does not cover the complete alpha-helix F and turn connecting alpha-helix F and beta-strand s3A, but is restricted to the hinge region between alpha-helix F and the main part of the PAI-1 Molecule. The monoclonal antibody MA-33H1F7 is a 'switching' antibody, capable of inducing a non-inhibitory substrate form of PAI-1. It was shown to inhibit PAI-1 in a dose dependent manner. Aliases PAI-1, endothelial plasminogen activator inhibitor, serpin E1 Immunogen Human PAI-1/t-PA complex
-
You are here:
